David Morrow is an Acute Myocardial Infarction Research physician affiliated with Brigham and Women's Hospital. OpenAlex indexes 1,062 publications with 100,166 citations (h-index 137); ClinicalTrials.gov lists 3 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Cardiovascular Disease profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
David Morrow, MD, is affiliated with Brigham and Women's Hospital. The public record shows 1,062 publications with 100,166 citations (h-index 137), centered on Acute Myocardial Infarction Research, Cardiac Imaging and Diagnostics, Mechanical Circulatory Support Devices. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 8 companies.
- Most recent indexed publication: 2026 · Circulation. Heart failure
- Top research focus: Acute Myocardial Infarction Research
- 3 registered trials on ClinicalTrials.gov
- Open Payments reporting from 8 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 44 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 510.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:
- Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care
Sponsor: 4TEEN4 Pharmaceuticals GmbH
- Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial
Sponsor: The TIMI Study Group
Industry payments
Updated 14 Oct 2026
8 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20251 payment
- AngioDynamics, Inc.Program year20251 payment
- ROCHE DIAGNOSTICS INTERNATIONAL LTDProgram year20248 payments$17,313openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
81.3%Statin30.1%Atorvastatin Calcium80%Rosuvastatin Calcium20%Part D≥61 patientsBeta blocker14.6%Metoprolol Succinate76%Atenolol14%Carvedilol11%Part D<11 patients+ 10 more classes in this area
Blood & clotting
10.6%Factor Xa inhibitor7.1%Eliquis70%Xarelto30%Part D<11 patientsP2Y12 inhibitor3.4%Clopidogrel100%Part D<11 patientsMetabolism & gastrointestinal
8.1%SGLT2 inhibitor6.7%Jardiance100%Part D≥15 patientsPotassium supplement1.4%Potassium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Variation in Vasoactive Treatment Selection for Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network (CCCTN).
Circulation. Heart failure
Article2026 - Ultrasound-assisted thrombolysis for intermediate-high risk pulmonary embolism: HI-PEITHO trial in perspective.
European heart journal. Acute cardiovascular care
Article2026 - Haemodynamic monitoring and management of the hypotensive out-of-hospital cardiac arrest patient in the adult intensive care unit: a clinical consensus statement of the Association for Acute CardioVascular Care of the ESC.
European heart journal. Acute cardiovascular care
Article2026 - Contemporary Practice Patterns of Vasoactive Use in Cardiogenic Shock in the American Heart Association Cardiogenic Shock Registry.
Journal of the American Heart Association
Article2025 - In perspective: slow is safe, fast is final-timing matters in fractional flow reserve-guided complete revascularization for ST-segment elevation myocardial infarction with multivessel disease.
European heart journal. Acute cardiovascular care
Article2025
Most-cited works
by citation count (OpenAlex)- 01Fourth universal definition of myocardial infarction (2018)Article5,847 citations2018
- 022013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial InfarctionArticle4,730 citations2012
- 03Fourth Universal Definition of Myocardial Infarction (2018)Article4,129 citations2018
- 04Fourth Universal Definition of Myocardial Infarction (2018)Article3,720 citations2018
- 05Third universal definition of myocardial infarctionArticle3,076 citations2012
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/david-morrow-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/David-A-Morrow-38363903
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
esc365.escardio.org/person/132
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →esc365.escardio.org ↗ - Other
timi.org/senior-investigators
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →timi.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Ridker, MD
Brigham and Women's Hospital
Scott Solomon, MD
Brigham and Women's Hospital
Marc Pfeffer, MD
Brigham and Women's Hospital
Marc Sabatine, MD
Brigham and Women's Hospital
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)